We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Imugene reported updated Phase II results for HER-Vaxx on Monday, saying that adding the experimental B-cell peptide immunotherapy vaccine to chemotherapy led to an overall response rate (ORR) of 50% in certain patients with gastric cancer.
Australian biotech Imugene says its HER2 vaccine hit the mark in a phase 1b trial, setting up a phase 2 study that will start recruiting patients in the new year.....